Literature DB >> 28661220

Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.

Siew Mei Yap1, Nuala McNicholas1, Michael Hutchinson1, Christopher McGuigan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28661220     DOI： 10.1177/1352458517719151

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  2 in total

1.  Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon.

Authors:  Marco Puthenparampil; Francesca Rinaldi; Lisa Federle; Chiara Cazzola; Paola Perini; Paolo Gallo
Journal:  Ther Adv Neurol Disord       Date:  2017-11-29       Impact factor: 6.570

2.  Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis.

Authors:  Hans-Klaus Goischke
Journal:  Ther Clin Risk Manag       Date:  2019-07-12       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.